





XIENCE: Proven Performance in Thousands of Patients



Promus Element evaluated in 100 simple patients with single, *de novo* lesions in PLATINUM QCA⁶

- 100.0% pre-dilatation
- 91.0% post-dilatation
- 83% IVUS guided implantation



1. Source: Agrawal et al, Biomaterials Vol 13, No. 3, 1992.
2. XIENCE PRIME 3.0 x 18 mm, Promus Element 3.0 x 20 mm.
3. Stone, G. W., A. Rizvi, et al. (2010). "Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease." N Engl J Med 362 (18): 1663-1674.
4. Kedhi, E., K. S. Joesoef, et al. "Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial." Lancet 375 (9710): 201-209.
5. Serruys, P. W., S. Silber, et al. (2010). "Comparison of zotarolimus-eluting and everolimus-eluting coronary stents." N Engl J Med 363(2): 136-146.
6. Dr. Ian Meredith. PLATINUM QCA 9-month Results Presentation. TCT 2010.

All photos taken by and on file at Abbott Vascular. Data on file at Abbott Vascular. Radial strength data based on bench top testing.

Abbott International BVBA

Park Lane, Culliganlaan 2B, B-1831 Diegem, Belgium Tel: 32.2.714.14.11

Information contained herein for distribution for Europe, Middle East and Africa ONLY.

Please check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force.

This product is intended for use by or under the direction of a physician. Prior to use, it is important to read the package insert thoroughly for Instructions for Use, warnings and potential complications associated with use of this device.

XIENCE V, XIENCE PRIME, MULTILINK are trademarks of the Abbott Group of Companies. Resolute is a trademark of Medtronic, Inc. Promus Element, Taxus Liberté and Taxus Express are trademarks of Boston Scientific, Inc. Cyper is a trademark of Johnson and Johnson.


RESOLUTE All Comers is a clinical trial of Medtronic

SPIRIT IV is an Abbott Vascular sponsored study. Abbott does not promote out of intended use for its products.

Compare is an investigator-sponsored, single-center, prospective RCT testing XIENCE V vs. TAXUS Liberté in 1,800 all comer, real-world patients.

Visit our website at www.XiencePrime.com

©2011 Abbott Laboratories. All rights reserved. LT2930108 Rev. A 12/10 - 1-EH-1-0748-01 02/2011





Xience PRIME

Everolimus Eluting
Coronary Stent System

XIENCE PRIME vs. Promus Element
A closer look at design differences

XIENCE PRIME is built on XIENCE V DES technology.
Information contained herein for distribution for Europe, Middle East and Africa ONLY.


 **Abbott**
A Promise for Life

XIENCE PRIME: Designed for Outstanding Deliverability with Optimal Scaffolding and Radial Strength

XIENCE PRIME

Leverages proven MULTI-LINK heritage




3 link design for uniform scaffolding and minimal plaque prolapse



Promus Element

New stent design

2 link design required to reduce stiffness, leads to uneven scaffolding on a bend




Radial Strength > 3X Maximum Arterial Pressure¹

XIENCE PRIME	Cypher Select+	ENDEAVOR Resolute	Promus Element
✓	✓	✓	✓

XIENCE PRIME: Designed for Accurate Placement and Minimal Vessel Injury

XIENCE PRIME




- Stent edge at mid-marker for accurate placement
- Short balloon taper for minimal vessel injury

Promus Element



XIENCE PRIME²



- Minimal shortening upon deployment for accurate placement

Promus Element²

